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Abstract
Background: Use of human mesenchymal stromal cells (MSCs) is a promising strategy for cell therapy in injured
tissues recovery. However, MSCs acquire genetic changes when cultivated in vitro that make them more susceptible
to undergo neoplastic transformation. Therefore, genomic integrity of stem cells should be monitored carefully for
the use in basic research and clinical trials, including karyotype analysis to confirm the absence of genetic
instability. Here, we report a case of a male 67-year-old patient selected to join the study: “Autologous
transplantation of mesenchymal cells for treatment of severe and refractory ischemic cardiomyopathy”. He
underwent nephrectomy for malignant tumor on the right kidney. Cytogenetic analysis on a bone marrow sample
showed a normal karyotype: 46,XY[20]. However, the MSC at second passage showed a hyperdiploid clone, with
clonal trisomies of chromosomes 4, 5, 10 and X. In order to investigate more, another sample from the same
patient was used for a second cultivation and, at third passage, these cells showed a clonal translocation
t(9;18)(p24;q11). The recurrent aberrations in MSC may indicate the beginning of a spontaneous transformation in
culture, so, these cells were not used for cell therapy. Several analyses were performed at the Center for Cell
Technology (152 samples), however this was the only case to show clonal cytogenetic abnormalities. Interestingly,
two distinct clonal alterations were seen in two parallel cell cultivations from the same patient, suggesting a
propensity for genetic instability. This highlights the need to evaluate these cells on a case-by-case basis, especially
in patients with a history of cancer. Although there is controversy about the use of cells with cytogenetic
abnormality for therapy, because their tumorigenic doubtful potential, we decided against the use of these cells for
regenerative medicine.
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Case presentation: Here, we report a case of a male 67-year-old patient selected to join the study: “Autologous
transplantation of mesenchymal cells for treatment of severe and refractory ischemic cardiomyopathy”. He
underwent nephrectomy for malignant tumor on the right kidney. Cytogenetic analysis on a bone marrow sample
showed a normal karyotype: 46,XY[20]. However, the MSC at second passage showed a hyperdiploid clone, with
clonal trisomies of chromosomes 4, 5, 10 and X. In order to investigate more, another sample from the same
patient was used for a second cultivation and, at third passage, these cells showed a clonal translocation
t(9;18)(p24;q11). The recurrent aberrations in MSC may indicate the beginning of a spontaneous transformation in
culture, so, these cells were not used for cell therapy. Several analyses were performed at the Center for Cell
Technology(152 samples), however this was the only case to show clonal cytogenetic abnormalities. Interestingly,
two distinct clonal alterations were seen in two parallel cell cultivations from the same patient, suggesting a
propensity for genetic instability. This highlights the need to evaluate these cells on a case-by-case basis, especially
in patients with a history of cancer.
Conclusions: Although there is controversy about the use of cells with cytogenetic abnormality for therapy,
because their tumorigenic doubtful potential, we decided against the use of these cells forregenerative medicine.
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Background
Use of human mesenchymal stromal cells (MSCs) is a
promising strategy for cell therapy in injured tissues re-
covery. However, MSCs acquire genetic changes when
cultivated in vitro that make them more susceptible to
undergo neoplastic transformation. Therefore, genomic
integrity of stem cells should be monitored carefully for
use in basic research and clinical trials [1]. MSCs, like
products of advanced therapy, should satisfy all the re-
quirements for human use of medicinal products, includ-
ing karyotype analysis to confirm the absence of genetic
instability, to ensure their quality and safety [2]. At the
Center for Cell Technology (CTC-PUCPR), we regularly
perform cytogenetic analyses (G-band karyotyping) for
quality control of the cells.
Case presentation
Here, we report the case of a 67-year-old patient, male,
who underwent coronary artery bypass grafting at 54 years
of age after a diagnosis of myocardial infarction. An angio-
plasty and 13 coronary angiography tests were performed.
In 1992, he underwent nephrectomy for a malignant
Fig. 1 Normal karyotype. Karyogram before cell expansion (bone marrow cells). Karyotype: 46,XY
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Fig. 2 Karyotype with trisomies. Karyogram after cell expansion, from the first cultivation (mesenchymal stem cells at second passage). Karyotype:
43,XY, +2,+4,+5,−10,−11,−14,−15,−18,−22
Fig. 3 Karyotype with translocation. Karyogram after cell expansion, from the second cultivation (mesenchymal stem cells at third passage).
Karyotype: 46,XY, t(9;18)(p24;q11)
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tumor in the right kidney. Scintigraphy performed in 2014
showed moderate and transient hypocaptation (ischemia)
in the anteroseptal middle and basal region of the left
ventricle. The patient was then enrolled in the study “Au-
tologous transplantation of mesenchymal cells for treat-
ment of severe and refractory ischemic cardiomyopathy”
(Local Ethics Committee number: 5250). His bone mar-
row mononuclear cells were collected and isolated by per-
forming density gradient centrifugation and were used as
a source of MSCs. These cells were loaded onto Histopa-
que® (1.077 g/mL; Sigma Chemical Co., St. Louis, MO)
and were seeded in culture flasks at a density of 2 × 106
cells/cm2. MSCs were cultivated in Iscove’s modified
Dulbecco’s medium (Gibco™) supplemented with 15 %
fetal bovine serum (Gibco™), in a humidified incubator at
37 °C with an atmosphere of 5 % carbon dioxide. After the
adhesion of MSCs to the flasks, their culture medium was
changed every 3–4 days. After reaching approximately
80 % confluence, the MSCs were dissociated using 0.25 %
trypsin–ethylenediaminetetraacetic acid (EDTA—Sigma–
Aldrich) and were continually expanded at least until the
second passage (P2). These cells were evaluated for per-
forming cytogenetic studies; immunophenotyping; and
osteogenic, adipogenic, and chondrogenic differentiation
assays [3, 4], according to the minimal step of the standard
criteria established by the International Society for Cellu-
lar Therapy [5].
Cytogenetic analyses were performed before and after
cell expansion. Standard cytogenetic procedures were
used to perform the cytogenetic analysis of the bone
marrow sample. This patient showed a normal karyotype:
46,XY[20] (Fig. 1).
MSCs were evaluated using a protocol described in
our previous study [6]. Five MSC samples obtained from
different passages (P) were analyzed. In the first culti-
vation, the MSC at second passage (P2) showed a
hyperdiploid clone (Fig. 2), with a composite karyotype:
43 ~ 52,XY,+X,+4,+5,+10[cp4]/46,XY[18], and non-clonal
trisomies:+2,+12,+20.
This sample was not approved for infusion according
to the criteria established by the CTC-PUCPR and those
published previously [7, 8]. After that, the MSCs from
P4 and P5 showed a normal karyotype, 46,XY[26] and
44 ~ 46,XY[13], respectively.
In order to investigate more, another sample of
mononuclear cells (that had been frozen for backup)
from the same patient, was used for a second cultiva-
tion. At P3, these cells showed a clonal translocation:
46,XY,t(9;18)(p24;q11)[8]/46,XY[5] (Fig. 3). At P5 the
karyotype was 26 ~ 44,XY[10].
Out of all cytogenetic analyses performed at the CTC-
PUCPR (152 samples), this was the only case to show
clonal cytogenetic abnormalities. Therefore, these cells
were not used for cell therapy.
Different researchers have different views regarding
the use of cells with cytogenetic abnormalities for cell the-
rapy because of their tumorigenic doubtful potential.
Karyotype abnormalities are frequently observed in
pluripotent cells, but also occur in adult stem cells. This
has caused discussion between different groups about
the risk factors for tumorigenic potential [9]. Sensebé et
al. [10] suggested that genomic stability observed in
MSC is robust and that there was no significant risk of
neoplastic transformation. They stated that the presence
of acquired chromosomal aberrations in the first mo-
ment, followed by a normal karyotype, suggested that
this aberration did not confer any growth advantage.
In response to the above suggestion, Uri Ben David
[11] argued that there are two types of genomic aberra-
tions: (1) transient aberrations, which occasionally appear
in culture but are disadvantageous and hence disappeared
during propagation, and (2) advantageous recurrent aber-
rations, which rapidly accumulate in the culture in a
clonal manner. These two types of genomic aberrations
exist simultaneously in stem cell cultures. Sensebé dis-
cussed the former type of aberrations. However, it should
be noted that aberrant cells can outgrow normal cells.
Therefore, clonal aberrations in MSCs may indicate the
initiation of a spontaneous transformation in a culture. In
addition, each stem cell type can acquire distinct recurrent
chromosomal abnormalities. Importantly, the common
aberrations in stem cell cultures resemble characteristic
aberrations in tumors cells from same cell lineages [11].
Both the types of aberrations identified in our patient
have been described in several types of cancers (http://
cgap.nci.nih.gov/Chromosomes/RecurrentAberrations)
[12]. Hyperdiploid karyotypes, including trisomies de-
tected in this case, are common in leukemias and solid
tumors. Translocations involving 18q11 have been de-
scribed in several cases of leukemia and sarcomas, of
mesenchymal origin.
It is important to note that aberrations identified in
this study, i.e., trisomies (aneuploidies) and translocation
(structural), were clonal. They were determined by G-
band karyotyping, which is the gold standard technique
for detecting clonal abnormalities (both numeric and
structural) in cultured cells. This is important because
recurrence of clonal chromosomal aberrations is a char-
acteristic of cancers.
Therefore, Barkholt [7] suggested performing a karyotyp-
ing analysis in order to exclude products containing cells
with abnormalities (which potentially confer a proliferative
advantage) according to criteria mentioned in the “Defin-
ition of a clone” established by the International System for
Human Cytogenetic Nomenclature (2013) [13].
Interestingly, two distinct clonal alterations were seen
in two parallel cell cultivations from the same patient,
suggesting a propensity for genetic instability probably
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associated with the cancer previous history of this pa-
tient. This highlights the need to evaluate these cells on
a case-by-case basis, especially in patients with a history
of cancer. In this case, separated runs in culture resulted
in the emergence of different end products (different
clonal chromosome aberrations). This is evidence of the
population’s genome diversity, which is increased by
chaotic chromosome changes, during the chromosome
instability observed in genome evolution of tumor cells.
In this process, there is a phase, referred to as punctuated/
discontinuous, and it is characterized by the presence of
non-clonal aberrations and transitional clonal aberrations
[14], as we observed on two cultivations.
On another hand, the emergence of aneuploidies
(changes in chromosome number) during cell culture is
common, and some studies have shown that this is not
necessarily associated with tumor formation in immu-
nodeficient mice [15]. However, Barkholt [7] stated that
even though transformed cells do not seem to undergo
tumor formation, this risk should be considered because
the characteristics of these abnormal cells are uncertain
and because the follow-up of patients is limited.
Conclusion
In practice, the decision to infuse cells with abnormal kar-
yotypes should be taken within a few hours. If an aberra-
tion is detected in cells from P2 when a patient is about to
receive these cells, there is no time to wait for the results
of cytogenetic analyses of cells from subsequent passages
to determine whether this aberration is temporary. There
are no lists available in the literature about recurrent aber-
rations in MSCs—as there is for neoplastic cells [12]—nor
of which aberration would be transitory and which ones
would be potentially tumorigenic. Therefore, we decided,
similar to that suggested by Muntion et al. [16], against
the use of these cells for regenerative medicine.
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